Actively Recruiting
Study of Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy PULSAR Combined With Immune Checkpoint Inhibitors for Advanced Liver Cancer
Led by Samsung Medical Center · Updated on 2026-10-21
38
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether adding PULSAR, a personalized adaptive stereotactic radiotherapy, to standard immunotherapy can better control high-risk advanced hepatocellular carcinoma liver cancer in adults. This phase II study aims to determine the percentage of participants alive without cancer progression 12 months after starting PULSAR and to assess the safety of this combination treatment. There is no comparison group results will be compared to existing data on immunotherapy alone. Participants continue their usual immune checkpoint inhibitor therapy while receiving 2 to 3 PULSAR radiotherapy sessions spaced 3 to 4 weeks apart. Each radiotherapy session delivers 8-12 Gy per pulse using photons or protons, with CT-based adaptive re-planning before each pulse to adjust the treatment based on tumor response. This approach personalizes therapy by reducing target volume as the tumor shrinks. During the study, participants provide blood samples and complete symptom questionnaires. They undergo regular checkups and imaging scans for up to three years to monitor cancer status and treatment effects. Researchers will measure progression-free survival at 12 months as the primary outcome and track additional outcomes like overall survival, tumor response, and adverse events throughout the follow-up period.
CONDITIONS
Brief Title
PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer
Research Team
N
Nalee Kim, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here